淼淼小主的个人主页 - 老虎社区

淼淼小主

淼淼小主

暂无个人介绍

IP属地：海外

4关注

0粉丝

3主题

0勋章

2021-08-27

$Inovio Pharmaceuticals Inc(INO)$在巴西第三期临床试验获批，有这么振奋人心的消息，还这尿性，这股真是甘心被做空，扶不起的阿斗！

2020-06-23

$Inovio Pharmaceuticals Inc(INO)$买定离手啦喂！

2020-05-26

$瑞幸咖啡(LK)$回光返照吗？

2020-05-20

自作孽，不可活

瑞幸退市后将如何活下去？

2020-03-19

$Co-diagnostics Inc.(CODX)$$Aytu BioScience, Inc.(AYTU)$$罗氏控股(RHHBY)$这就是马爸爸今天运了50万套试剂盒去米国的后果吗？

2020-03-17

临床试验药物行不行，岂由华尔街分析师说了算？

“人民的希望”瑞德西韦让业界专家大失所望！

2020-03-12

$Co-diagnostics Inc.(CODX)$心脏病者慎入！

2020-03-12

$Co-diagnostics Inc.(CODX)$财报又赶不出来了？

2020-03-04

$吉利德科学(GILD)$隔壁$Moderna, Inc.(MRNA)$难兄难弟，跟你同一行情

2020-03-02

$Forty Seven Inc.(FTSV)$吉利德以每股95.5美元收购47 65%的股份

2020-02-28

$Moderna, Inc.(MRNA)$ 多次喊停后，终于冷静下来了

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3544167465922949","uuid":"3544167465922949","gmtCreate":1581073443679,"gmtModify":1582779888235,"name":"淼淼小主","pinyin":"mmxzmiaomiaoxiaozhu","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":3,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":810798140,"gmtCreate":1630007656480,"gmtModify":1704954458177,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>在巴西第三期临床试验获批，有这么振奋人心的消息，还这尿性，这股真是甘心被做空，扶不起的阿斗！","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>在巴西第三期临床试验获批，有这么振奋人心的消息，还这尿性，这股真是甘心被做空，扶不起的阿斗！","text":"$Inovio Pharmaceuticals Inc(INO)$在巴西第三期临床试验获批，有这么振奋人心的消息，还这尿性，这股真是甘心被做空，扶不起的阿斗！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/810798140","isVote":1,"tweetType":1,"viewCount":3754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":954660955,"gmtCreate":1592912521677,"gmtModify":1704200542918,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>买定离手啦喂！","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>买定离手啦喂！","text":"$Inovio Pharmaceuticals Inc(INO)$买定离手啦喂！","images":[{"img":"https://static.tigerbbs.com/ad7b529dcba85594aa758be72d4b34e8","width":"1072","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/954660955","isVote":1,"tweetType":1,"viewCount":2494,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":953514935,"gmtCreate":1590484722327,"gmtModify":1704192614436,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LK\">$瑞幸咖啡(LK)$</a>回光返照吗？","listText":"<a href=\"https://laohu8.com/S/LK\">$瑞幸咖啡(LK)$</a>回光返照吗？","text":"$瑞幸咖啡(LK)$回光返照吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/953514935","isVote":1,"tweetType":1,"viewCount":16784,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":959456092,"gmtCreate":1589988177216,"gmtModify":1704191439128,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"自作孽，不可活","listText":"自作孽，不可活","text":"自作孽，不可活","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/959456092","repostId":"1127099160","repostType":4,"repost":{"id":"1127099160","kind":"news","pubTimestamp":1589971869,"share":"https://www.laohu8.com/m/news/1127099160?lang=&edition=full","pubTime":"2020-05-20 18:51","market":"us","language":"zh","title":"瑞幸退市后将如何活下去？","url":"https://stock-news.laohu8.com/highlight/detail?id=1127099160","media":"财经十一人","summary":"一年前的5月17日，瑞幸咖啡登陆纳斯达克，一时间风光无两；一年后的今天，瑞幸咖啡被交易所要求摘牌。这家成立不到三年的公司创造了最快上市和退市两项记录，市值也已从年初的超百亿美元跌至仅剩11亿美元。\n一","content":"<div>\n<p>一年前的5月17日，瑞幸咖啡登陆纳斯达克，一时间风光无两；一年后的今天，瑞幸咖啡被交易所要求摘牌。这家成立不到三年的公司创造了最快上市和退市两项记录，市值也已从年初的超百亿美元跌至仅剩11亿美元。\n一瞬间，曾经的资本神话轰然倒下，但瑞幸这家公司的故事还没有到终局。5月20日上午，《财经》记者实地走访发现，多家瑞幸门店的运营均保持正常，店员和顾客的心态都很平稳。几名消费者表示，造假事件对他们没有什么...</p>\n\n<a href=\"https://mp.weixin.qq.com/s/EJBgNZmbgpoIB0u7DMHMKQ\">Web Link</a>\n\n</div>\n","source":"cjsyr","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞幸退市后将如何活下去？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞幸退市后将如何活下去？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-05-20 18:51 北京时间&nbsp;&nbsp;&nbsp;<a href=https://mp.weixin.qq.com/s/EJBgNZmbgpoIB0u7DMHMKQ><strong>财经十一人</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一年前的5月17日，瑞幸咖啡登陆纳斯达克，一时间风光无两；一年后的今天，瑞幸咖啡被交易所要求摘牌。这家成立不到三年的公司创造了最快上市和退市两项记录，市值也已从年初的超百亿美元跌至仅剩11亿美元。\n一瞬间，曾经的资本神话轰然倒下，但瑞幸这家公司的故事还没有到终局。5月20日上午，《财经》记者实地走访发现，多家瑞幸门店的运营均保持正常，店员和顾客的心态都很平稳。几名消费者表示，造假事件对他们没有什么...</p>\n\n<a href=\"https://mp.weixin.qq.com/s/EJBgNZmbgpoIB0u7DMHMKQ\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/ac896f43535354e5c6c78eca56391522","relate_stocks":{},"source_url":"https://mp.weixin.qq.com/s/EJBgNZmbgpoIB0u7DMHMKQ","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127099160","content_text":"一年前的5月17日，瑞幸咖啡登陆纳斯达克，一时间风光无两；一年后的今天，瑞幸咖啡被交易所要求摘牌。这家成立不到三年的公司创造了最快上市和退市两项记录，市值也已从年初的超百亿美元跌至仅剩11亿美元。\n一瞬间，曾经的资本神话轰然倒下，但瑞幸这家公司的故事还没有到终局。5月20日上午，《财经》记者实地走访发现，多家瑞幸门店的运营均保持正常，店员和顾客的心态都很平稳。几名消费者表示，造假事件对他们没有什么影响，想喝咖啡的时候还是会来买。\n自成立以来，瑞幸一直依靠着外部融资快速开店、补贴用户，这种不计成本的做法使公司每个季度的财务报表上都会出现数亿元的亏损。现在人们关心的是，失去外部的“输血”渠道之后，瑞幸是否有能力靠自身的“造血”功能生存下去？\n陆正耀在5月20日凌晨发出的个人声明中强调了将瑞幸继续下去的决心，表示将“倾尽全力维持门店运营”。“我坚信瑞幸咖啡的商业模式和商业逻辑是成立的，”他写道，同时他还“真心恳请社会各界能够给予宽容和支持。”\n一位瑞幸工作人员也告诉《财经》记者，针对此次纳斯达克要求退市的事件，公司没有发布正式的内部信，仅在部门群中通知，表示公司运营层面一切稳定，希望员工不要受到影响，“无论如何，还是会持续为客户创造价值”。\n瑞幸已准备申请就退市问题举行听证会，但《财经》记者采访的多位业内人士认为，瑞幸咖啡退市大概率已成定局。“瑞幸退市，投资者直接损失最大，但是也让瑞幸自身失去了上市公司的融资渠道及品牌效应，无论其客户或员工利益都会因此受损。”美股维权律师郝俊波向《财经》记者表示。\n自4月7日起，瑞幸咖啡股票一直停牌至今。纳斯达克计划于美东时间5月20日上午7点（北京时间5月20日晚上19:00）恢复瑞幸咖啡的交易。\n“今晚的开盘可能比较惨淡。在大概率摘牌情况下，存量投资者的资金有非常强烈的出逃需求。因为一旦摘牌，剩余的股权就丧失流动性，几乎与破产无异。”资深美股研究者、安澜资本高管陈达向《财经》记者表示。\n退市成定局？\n5月19日晚瑞幸咖啡公告，公司于5月15日收到纳斯达克上市资格部门的书面通知，纳斯达克交易所决定将公司摘牌。公司计划就此申请举行听证会，在听证会结果出炉前，将继续在纳斯达克上市。\n“上市公司可能会因为各种不同原因摘牌，但是因造假被摘牌的很少见，基本上是最坏的原因，比业绩不佳影响更糟糕。”郝俊波表示。他认为，退市不仅让瑞幸难以通过美国股市融资，也会进一步降低其商业信誉，将会对品牌产生十分不利的影响。\n纳斯达克上市资格部门指出了摘牌决定的两个依据：根据纳斯达克交易所上市规则5101，瑞幸咖啡于4月2日披露的虚假交易引发了公众利益的担忧；根据纳斯达克交易所上市规则5250，瑞幸咖啡在过去未能公开披露有效信息，并通过此前的商业模式进行了虚假交易。\n郝俊波认为，听证会争论的焦点可能会集中在上述两方面。安澜资本陈达则认为，听证会争辩的焦点，或将是瑞幸是否为了消除财务造假的影响做出了足够的努力，以及经过大刀阔斧改革后的瑞幸是否还满足挂牌上市的要求。\n此前，瑞幸咖啡董事长陆正耀表示，瑞幸已经非常配合SEC、其他监管方以及其他利益相关方的调查，也开除了相关的管理层并重整了董事会，在这件事情上付出努力应该能够让瑞幸继续满足挂牌的要求。\n但是对于听证会的结果，业内人士并不乐观。资深投行人士王骥跃认为，基本没有悬念，瑞幸咖啡退市成定局。\n“瑞幸咖啡大概率会退市，主要有两个原因：一是自身承认造假；二是未披露重大信息。这两者可争辩的空间都非常少。”瑞幸咖啡集体诉讼案在美国代理律师刘龙珠向《财经》记者表示。\n王骥跃认为，公司可能会辩称造假行为只是个人行为而不是公司行为。“我认为这样大规模的造假行为并非一人就可以搞定。”\n安澜资本陈达也向《财经》记者表示，瑞幸要求听证会的目的或就在于说服监管相信瑞幸的问题不是整体公司的问题，而是“个别相关人员”。\n按照规定，被纳斯达克勒令强制退市的企业，可以申请听证，最后可上诉到美国证券交易委员会（SEC），SEC的决定将是最终判决。本次听证失败后，瑞幸咖啡仍可以继续进行申诉。\n“如果听证会失败，瑞幸咖啡可以向联邦法庭申诉。但是即便申诉，我个人觉得成功概率不大。毕竟，瑞幸咖啡是主动承认造假。”刘龙珠告诉《财经》记者。\n对于强制摘牌，瑞幸咖啡董事长陆正耀回应称：“纳斯达克不等最终调查结果就要求公司退市，出乎意料，我个人深感失望和遗憾。”\n陆正耀在声明中称，“创业以来，我挣到的钱几乎全部投入到了实体企业中，质押瑞幸咖啡股票所得在资金，也全部用于支持旗下各个企业的经营发展，没有用于个人挥霍，更没有转移资产，对此，我愿意接受任何调查。”\n“过去一个多月，我一直处于深深的痛苦和自责之中，夜不能寐。公司如果退市，面临的困难和压力必将继续加大，但不论怎样，我都会倾尽全力维持门店运营，竭尽所能挽回股东损失，让瑞幸这个品牌能够走下去。”他说。\n投资者们早已开始了集体诉讼索赔。另一边，瑞幸咖啡董事长陆正耀也对曾经的亲密伙伴瑞信发起了诉讼。\nDebtwire援引5月6日的法庭文件报道称，陆正耀的旗下公司已经起诉瑞信，要求后者就涉嫌违反一项已被加速的5.32亿美元贷款安排中的职责作出赔偿。\n起因在于4月3日，瑞信代表其香港分行、高盛、巴克莱、CICC Hong Kong Finance、海通国际投资和摩根士丹利发出强制性提前还款事件通知。\n投资人索赔进行中\n瑞幸跌入造假深渊，持股的机构和个人也将遭受损失。\n根据老虎证券的数据，95家机构共持有瑞幸咖啡股票3783股，持股比例为15.74%。\n截至5月1日，在机构投资者中，资本研究与管理公司持有1008.77万股，持股比例达到3.98%；美国银行持有497.37万股，贝莱德持有483.82万股，纽约人寿持有357.7万股，占比分别为1.96%、1.91%、1.41%。其他机构投资者还有领航、高盛、威灵顿资产管理等。投行方面，摩根士丹利持有瑞幸咖啡364.91万股，持股比例为1.44%。\n瑞幸的个人投资者则遍布世界各地。根据相关规则，从交易所退市的证券将进入粉单市场，这个市场流动性较差，没有信息披露要求，因此垃圾股遍地。有投资者认为，瑞幸管理层应考虑私有化，而非进入粉单市场。\n据《财经》记者了解，目前已有很多投资者在考虑对瑞幸咖啡发起集体诉讼。证券律师郝俊波代理了5位瑞幸投资者的诉讼，其中一人来自国内，其余4人来自四个不同国家。郝俊波介绍，目前五位投资者已经在申请成为首席原告。\n对于瑞幸被纳斯达克下发摘牌通知，郝俊波表示，这不影响诉讼程序，整个诉讼过程可能会长达两到三年，关于赔偿金额，会根据虚假陈述造成的投资损失来计算。\n“实际执行是个问题。”郝俊波对《财经》记者表示，“一般会由保险公司进行赔偿，但瑞幸高管可能参与了欺诈，保险公司可能就不赔了。目前案件还未进入审理阶段，这些还需要在诉讼程序中进一步确定。”\n瑞幸事件也引起了中国监管部门的高度关注。5月4日，国务院金融稳定发展委员会召开第二十八次会议，再次强调对资本市场造假行为“零容忍”。\n5月15日，中国证监会主席易会满在全国投资者保护宣传日上发表主旨演讲，其中针对瑞幸咖啡特别提到：“对于近期个别境外上市企业出现的涉嫌财务造假等问题，证监会正与境外相关监管机构保持密切沟通，将在跨境证券执法、审计监管等领域进一步加强合作。不管采取何种形式，不管在何地上市，上市公司都应当严格遵守相关市场的法律和规则，真实准确完整履行信息披露义务，维护好形象和信誉。”\n“中国监管部门提供司法协助，这样既可以行使管辖权，又可以弥补美国的监管空白，长远来看，处于严密的监管之下，对中概股无疑是利好。”郝俊波表示。\n瑞幸能否换个活法\n从4月2日自曝造假到现在，瑞幸咖啡一直保持着运营。\n《财经》记者5月20日来到瑞幸一家集合了堂食、自提和外送的门店，这里并未像4月瑞幸刚刚爆出财务造假之后那样，发生咖啡券“挤兑”现象，来买咖啡的用户不算多，15分钟内约有8位消费者来取咖啡。门店一位店员表示，店内不接受记者采访，一切联系必须通过公司。\n\n摄影／《财经》记者马霖\n在瑞幸的一家小鹿茶加盟商店，《财经》记者观察到，10分钟内并没有消费者来取用或者购买咖啡，比较冷清。\n有消费者向《财经》记者表示，瑞幸目前经历的一系列事件，不太会影响自己购买瑞幸咖啡，“想喝的时候，还是会购买。”\n如果失去上市公司资格和资本市场输血能力，瑞幸可能需要通过调高咖啡价格，才有可能持续经营。但涨价后是否能留住消费者，对瑞幸来说将是一个考验。\n有消费者表示，如果瑞幸未来取消补贴，涨价到星巴克30多元的水平，肯定不会购买，如果价格维持在20元出头的话是可以接受的。也有消费者表示，目前公司周围只有瑞幸，没有其他选择，所以如果涨价几块钱还是会考虑购买。\n另有消费者说，虽然7-11等便利店都有卖咖啡，但还是比较信任瑞幸这种连锁咖啡的品质，即使便利店咖啡只卖10元左右，也不会因为便宜而优先考虑购买便利店咖啡。\n一位投资人对瑞幸未来的运营比较悲观。“瑞幸退市的话，前景会很辛苦，它的业务模式是要靠比较大的资金规模去支持，本身的造血功能现在还没跟上来，要靠外部股权注入资金，现在估值又这么低。退市后，资金供给应该会告一段落，整个公司的运营我会感觉悲观一些。”\n亦有消费行业投资人表示，在中国做咖啡创业的确有一些难度，咖啡是一个很特殊的品类，在中国市场，培育增量用户、建立品牌心智需要花钱，没有钱很难做大，但瑞幸的激进，导致其资金窟窿很大，融钱需求紧迫，股权质押融资也需要好的股市表现，而好的股市表现又需要好看的财报，瑞幸最终是通过走造假这个“下下策”去粉饰财报，这是不可取的。\n“发展太快会有很多问题，包括对大规模资金的依赖，组织管理、业务执行难度增大，核心高管团队的心态很容易产生变化，导致计划、节奏、执行都容易‘变形’。”该投资人表示。\n他认为，瑞幸整体还是有收购价值的，只是价格是一个问题，另外品牌价值已经受到了冲击，它的供应链基础和门店渠道资源、IT系统仍有价值。\n有投资人认为，从瑞幸目前积累的门店和供应链能力来看，这家公司还有继续存活的可能性。“门店数量减少之后，供应链的资金压力也会降低，也便于资金周转。”一位关注瑞幸的投资人提到，“勒紧裤腰带，减少开支，还是有可能赚钱的，现在瑞幸还上线了电子产品、家居用品等品类，也能增加一些收入。”\n此外，他还提到，如果实在运营不起来，老股东们也不会放任不管，会寻找将公司低价出售的可能性，如果这条路也行不通，那就交给不良资产处置的机构。\n但一位关注消费领域的投资人认为，瑞幸的商业逻辑并不成立，“为了能快速上市，瑞幸必须讲一个高速增长的故事，因此大量的成本投入在供应链、门店扩张、营销宣传以及快速增加的人员管理上。”他告诉《财经》记者，“正常的餐饮零售门店的商业逻辑，应该是每卖出一样东西，都能赚钱，但瑞幸是每卖出一杯咖啡，都在亏钱。”","news_type":1},"isVote":1,"tweetType":1,"viewCount":3090,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":967154269,"gmtCreate":1584549731051,"gmtModify":1704354929725,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a><a href=\"https://laohu8.com/S/AYTU\">$Aytu BioScience, Inc.(AYTU)$</a><a href=\"https://laohu8.com/S/RHHBY\">$罗氏控股(RHHBY)$</a>这就是马爸爸今天运了50万套试剂盒去米国的后果吗？","listText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a><a href=\"https://laohu8.com/S/AYTU\">$Aytu BioScience, Inc.(AYTU)$</a><a href=\"https://laohu8.com/S/RHHBY\">$罗氏控股(RHHBY)$</a>这就是马爸爸今天运了50万套试剂盒去米国的后果吗？","text":"$Co-diagnostics Inc.(CODX)$$Aytu BioScience, Inc.(AYTU)$$罗氏控股(RHHBY)$这就是马爸爸今天运了50万套试剂盒去米国的后果吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/967154269","isVote":1,"tweetType":1,"viewCount":4197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":964415424,"gmtCreate":1584444908968,"gmtModify":1704354165722,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"临床试验药物行不行，岂由华尔街分析师说了算？","listText":"临床试验药物行不行，岂由华尔街分析师说了算？","text":"临床试验药物行不行，岂由华尔街分析师说了算？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/964415424","repostId":"1150330379","repostType":2,"repost":{"id":"1150330379","kind":"news","pubTimestamp":1584440319,"share":"https://www.laohu8.com/m/news/1150330379?lang=&edition=full","pubTime":"2020-03-17 18:18","market":"us","language":"zh","title":"“人民的希望”瑞德西韦让业界专家大失所望！","url":"https://stock-news.laohu8.com/highlight/detail?id=1150330379","media":"全球医生组织  ","summary":"被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir)，最新临床试验数据初步评估，让业界人士大失所望！\n这是最新传播方式认知：\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染","content":"<p><b>被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir)，最新临床试验数据初步评估，让业界人士大失所望！</b></p>\n<p><b>这是最新传播方式认知：</b></p>\n<p><img src=\"https://static.tigerbbs.com/5178d780395c6aeebadc23d7d1d846c3\"></p>\n<p>根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据，给出最乐观说法是「好坏参半或不及50%效果」。</p>\n<p>华尔街资深分析师表示在评估该项12名患者临床试验报告数据后，得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要！</p>\n<p>相关临床研究论文已发表在预印本服务器上。论文详述了12例新冠病毒患者的流行病学，临床病程和病毒学特征，包括3例接受瑞德西韦的治疗结果。该临床试验是由美国CDC应急小组人员开展的，确诊患者是从钻石公主号游轮接回来的患者。</p>\n<p>该报告称「对早期确诊的轻至中度新冠病毒感染患者进行了随机双盲对比治疗性试验，结果表明患者在疾病确诊后第二周出现恶化迹象。」</p>\n<p><b>具体讲，与未接受瑞德西韦治疗的患者相比，接受该药治疗患者的给氧需求，发烧和病毒感染症状改善之间没有「明显时间关联性」。</b></p>\n<p>该报告还陈述了服用瑞德西韦的患者出现恶心、呕吐、直肠出血和肝酶升高等不良反应(肝酶改变提示肝毒性潜在风险)，这表明该抗病毒治疗效果需要更长时间监测和观察。</p>\n<p>随着疫情全球大流行爆发，寻找药物治疗方法已经和疫苗研发同步进行了。今天由美国国立卫生研究院附属过敏与感染疾病研究所(NIH-NIAID) 主持的疫苗临床试验正式注射给第一位健康者，预期1-2月后才能初步评估安全性。</p>\n<p>吉利德研发的瑞德西韦是在去年埃博拉III期临床试验失败后被重新启用测试的。目前，在美国和中国还有其他4-5项临床试验同时进行中。吉利德也根据「同情法案」为数百名患者提供了该试验药品，本月底或下月初陆续还会有相关结果报道。</p>\n<p>业界专家认为新药临床试验，特别涉及目前重大疫情，所有试验药品和每项验证结果都会被反复仔细研究，寻找可能的有效迹象。因为无数患者期待着哪怕是微小希望(人民的希望)，包括最初个案例也会作为有价值线索分析。</p>\n<p>美国联邦政府的疫情特别行动小组专家指出，该论文尚未经过同行评审，试验结果还需要最终评估。FDA目前无法接受这样的数据审评。</p>\n<p>该论文作者指出「在美国确诊的患者总体疾病过程似乎比在中国观察到的患者要好些；大约42％的患者不需要住院治疗；但也提醒这一病情状况是否代表不同医疗水平或病毒谱系本身不断发演变展，仍有待研究」。</p>\n<p>还有业界人士提示该试验结果未经同行评审，在这种情况下各种已知药物引起的副作用可能会比通常情形下低很多。专家专家认为这是因为许多确诊患者已经服用了多种其他药，包括类固醇激素和抗生素等。</p>\n<p>此外，吉利德的「同情用药」通常针对病情恶化的患者。资深专家认为此药仍有可能缓减患者病情恶化。换句话说，该药应尽快给予患者以避免病情恶化，有可能产生一定效果。</p>\n<p>总之，鉴于目前临床试验小样本量和混合其他药品作用，凸显了评估该药临床疗效的难度。希望「纯粹」双盲对照试验也有相当难度，最终是否止步于III期试验或「被流产」都是未知数。</p>","source":"lsy1584440308046","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“人民的希望”瑞德西韦让业界专家大失所望！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“人民的希望”瑞德西韦让业界专家大失所望！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-03-17 18:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg><strong>全球医生组织  </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir)，最新临床试验数据初步评估，让业界人士大失所望！\n这是最新传播方式认知：\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据，给出最乐观说法是「好坏参半或不及50%效果」。\n华尔街资深分析师表示在评估该项12名患者临床试验报告数据后，得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要！\n相关...</p>\n\n<a href=\"https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150330379","content_text":"被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir)，最新临床试验数据初步评估，让业界人士大失所望！\n这是最新传播方式认知：\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据，给出最乐观说法是「好坏参半或不及50%效果」。\n华尔街资深分析师表示在评估该项12名患者临床试验报告数据后，得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要！\n相关临床研究论文已发表在预印本服务器上。论文详述了12例新冠病毒患者的流行病学，临床病程和病毒学特征，包括3例接受瑞德西韦的治疗结果。该临床试验是由美国CDC应急小组人员开展的，确诊患者是从钻石公主号游轮接回来的患者。\n该报告称「对早期确诊的轻至中度新冠病毒感染患者进行了随机双盲对比治疗性试验，结果表明患者在疾病确诊后第二周出现恶化迹象。」\n具体讲，与未接受瑞德西韦治疗的患者相比，接受该药治疗患者的给氧需求，发烧和病毒感染症状改善之间没有「明显时间关联性」。\n该报告还陈述了服用瑞德西韦的患者出现恶心、呕吐、直肠出血和肝酶升高等不良反应(肝酶改变提示肝毒性潜在风险)，这表明该抗病毒治疗效果需要更长时间监测和观察。\n随着疫情全球大流行爆发，寻找药物治疗方法已经和疫苗研发同步进行了。今天由美国国立卫生研究院附属过敏与感染疾病研究所(NIH-NIAID) 主持的疫苗临床试验正式注射给第一位健康者，预期1-2月后才能初步评估安全性。\n吉利德研发的瑞德西韦是在去年埃博拉III期临床试验失败后被重新启用测试的。目前，在美国和中国还有其他4-5项临床试验同时进行中。吉利德也根据「同情法案」为数百名患者提供了该试验药品，本月底或下月初陆续还会有相关结果报道。\n业界专家认为新药临床试验，特别涉及目前重大疫情，所有试验药品和每项验证结果都会被反复仔细研究，寻找可能的有效迹象。因为无数患者期待着哪怕是微小希望(人民的希望)，包括最初个案例也会作为有价值线索分析。\n美国联邦政府的疫情特别行动小组专家指出，该论文尚未经过同行评审，试验结果还需要最终评估。FDA目前无法接受这样的数据审评。\n该论文作者指出「在美国确诊的患者总体疾病过程似乎比在中国观察到的患者要好些；大约42％的患者不需要住院治疗；但也提醒这一病情状况是否代表不同医疗水平或病毒谱系本身不断发演变展，仍有待研究」。\n还有业界人士提示该试验结果未经同行评审，在这种情况下各种已知药物引起的副作用可能会比通常情形下低很多。专家专家认为这是因为许多确诊患者已经服用了多种其他药，包括类固醇激素和抗生素等。\n此外，吉利德的「同情用药」通常针对病情恶化的患者。资深专家认为此药仍有可能缓减患者病情恶化。换句话说，该药应尽快给予患者以避免病情恶化，有可能产生一定效果。\n总之，鉴于目前临床试验小样本量和混合其他药品作用，凸显了评估该药临床疗效的难度。希望「纯粹」双盲对照试验也有相当难度，最终是否止步于III期试验或「被流产」都是未知数。","news_type":1},"isVote":1,"tweetType":1,"viewCount":2096,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":965536991,"gmtCreate":1584021788613,"gmtModify":1704352600458,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a>心脏病者慎入！","listText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a>心脏病者慎入！","text":"$Co-diagnostics Inc.(CODX)$心脏病者慎入！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/965536991","isVote":1,"tweetType":1,"viewCount":2656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":965230655,"gmtCreate":1584014361677,"gmtModify":1704352447565,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a>财报又赶不出来了？","listText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a>财报又赶不出来了？","text":"$Co-diagnostics Inc.(CODX)$财报又赶不出来了？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/965230655","isVote":1,"tweetType":1,"viewCount":2031,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":983525009,"gmtCreate":1583333222101,"gmtModify":1704349495007,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>隔壁<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>难兄难弟，跟你同一行情","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>隔壁<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>难兄难弟，跟你同一行情","text":"$吉利德科学(GILD)$隔壁$Moderna, Inc.(MRNA)$难兄难弟，跟你同一行情","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/983525009","isVote":1,"tweetType":1,"viewCount":3081,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":983314905,"gmtCreate":1583151900507,"gmtModify":1704348781072,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FTSV\">$Forty Seven Inc.(FTSV)$</a>吉利德以每股95.5美元收购47 65%的股份","listText":"<a href=\"https://laohu8.com/S/FTSV\">$Forty Seven Inc.(FTSV)$</a>吉利德以每股95.5美元收购47 65%的股份","text":"$Forty Seven Inc.(FTSV)$吉利德以每股95.5美元收购47 65%的股份","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/983314905","isVote":1,"tweetType":1,"viewCount":3237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":989239941,"gmtCreate":1582823562483,"gmtModify":1704347938970,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>&nbsp;多次喊停后，终于冷静下来了","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>&nbsp;多次喊停后，终于冷静下来了","text":"$Moderna, Inc.(MRNA)$ 多次喊停后，终于冷静下来了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/989239941","isVote":1,"tweetType":1,"viewCount":1928,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":965536991,"gmtCreate":1584021788613,"gmtModify":1704352600458,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a>心脏病者慎入！","listText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a>心脏病者慎入！","text":"$Co-diagnostics Inc.(CODX)$心脏病者慎入！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/965536991","isVote":1,"tweetType":1,"viewCount":2656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":983525009,"gmtCreate":1583333222101,"gmtModify":1704349495007,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>隔壁<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>难兄难弟，跟你同一行情","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>隔壁<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>难兄难弟，跟你同一行情","text":"$吉利德科学(GILD)$隔壁$Moderna, Inc.(MRNA)$难兄难弟，跟你同一行情","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/983525009","isVote":1,"tweetType":1,"viewCount":3081,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":810798140,"gmtCreate":1630007656480,"gmtModify":1704954458177,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>在巴西第三期临床试验获批，有这么振奋人心的消息，还这尿性，这股真是甘心被做空，扶不起的阿斗！","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>在巴西第三期临床试验获批，有这么振奋人心的消息，还这尿性，这股真是甘心被做空，扶不起的阿斗！","text":"$Inovio Pharmaceuticals Inc(INO)$在巴西第三期临床试验获批，有这么振奋人心的消息，还这尿性，这股真是甘心被做空，扶不起的阿斗！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/810798140","isVote":1,"tweetType":1,"viewCount":3754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":954660955,"gmtCreate":1592912521677,"gmtModify":1704200542918,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>买定离手啦喂！","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>买定离手啦喂！","text":"$Inovio Pharmaceuticals Inc(INO)$买定离手啦喂！","images":[{"img":"https://static.tigerbbs.com/ad7b529dcba85594aa758be72d4b34e8","width":"1072","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/954660955","isVote":1,"tweetType":1,"viewCount":2494,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":964415424,"gmtCreate":1584444908968,"gmtModify":1704354165722,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"临床试验药物行不行，岂由华尔街分析师说了算？","listText":"临床试验药物行不行，岂由华尔街分析师说了算？","text":"临床试验药物行不行，岂由华尔街分析师说了算？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/964415424","repostId":"1150330379","repostType":2,"repost":{"id":"1150330379","kind":"news","pubTimestamp":1584440319,"share":"https://www.laohu8.com/m/news/1150330379?lang=&edition=full","pubTime":"2020-03-17 18:18","market":"us","language":"zh","title":"“人民的希望”瑞德西韦让业界专家大失所望！","url":"https://stock-news.laohu8.com/highlight/detail?id=1150330379","media":"全球医生组织  ","summary":"被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir)，最新临床试验数据初步评估，让业界人士大失所望！\n这是最新传播方式认知：\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染","content":"<p><b>被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir)，最新临床试验数据初步评估，让业界人士大失所望！</b></p>\n<p><b>这是最新传播方式认知：</b></p>\n<p><img src=\"https://static.tigerbbs.com/5178d780395c6aeebadc23d7d1d846c3\"></p>\n<p>根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据，给出最乐观说法是「好坏参半或不及50%效果」。</p>\n<p>华尔街资深分析师表示在评估该项12名患者临床试验报告数据后，得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要！</p>\n<p>相关临床研究论文已发表在预印本服务器上。论文详述了12例新冠病毒患者的流行病学，临床病程和病毒学特征，包括3例接受瑞德西韦的治疗结果。该临床试验是由美国CDC应急小组人员开展的，确诊患者是从钻石公主号游轮接回来的患者。</p>\n<p>该报告称「对早期确诊的轻至中度新冠病毒感染患者进行了随机双盲对比治疗性试验，结果表明患者在疾病确诊后第二周出现恶化迹象。」</p>\n<p><b>具体讲，与未接受瑞德西韦治疗的患者相比，接受该药治疗患者的给氧需求，发烧和病毒感染症状改善之间没有「明显时间关联性」。</b></p>\n<p>该报告还陈述了服用瑞德西韦的患者出现恶心、呕吐、直肠出血和肝酶升高等不良反应(肝酶改变提示肝毒性潜在风险)，这表明该抗病毒治疗效果需要更长时间监测和观察。</p>\n<p>随着疫情全球大流行爆发，寻找药物治疗方法已经和疫苗研发同步进行了。今天由美国国立卫生研究院附属过敏与感染疾病研究所(NIH-NIAID) 主持的疫苗临床试验正式注射给第一位健康者，预期1-2月后才能初步评估安全性。</p>\n<p>吉利德研发的瑞德西韦是在去年埃博拉III期临床试验失败后被重新启用测试的。目前，在美国和中国还有其他4-5项临床试验同时进行中。吉利德也根据「同情法案」为数百名患者提供了该试验药品，本月底或下月初陆续还会有相关结果报道。</p>\n<p>业界专家认为新药临床试验，特别涉及目前重大疫情，所有试验药品和每项验证结果都会被反复仔细研究，寻找可能的有效迹象。因为无数患者期待着哪怕是微小希望(人民的希望)，包括最初个案例也会作为有价值线索分析。</p>\n<p>美国联邦政府的疫情特别行动小组专家指出，该论文尚未经过同行评审，试验结果还需要最终评估。FDA目前无法接受这样的数据审评。</p>\n<p>该论文作者指出「在美国确诊的患者总体疾病过程似乎比在中国观察到的患者要好些；大约42％的患者不需要住院治疗；但也提醒这一病情状况是否代表不同医疗水平或病毒谱系本身不断发演变展，仍有待研究」。</p>\n<p>还有业界人士提示该试验结果未经同行评审，在这种情况下各种已知药物引起的副作用可能会比通常情形下低很多。专家专家认为这是因为许多确诊患者已经服用了多种其他药，包括类固醇激素和抗生素等。</p>\n<p>此外，吉利德的「同情用药」通常针对病情恶化的患者。资深专家认为此药仍有可能缓减患者病情恶化。换句话说，该药应尽快给予患者以避免病情恶化，有可能产生一定效果。</p>\n<p>总之，鉴于目前临床试验小样本量和混合其他药品作用，凸显了评估该药临床疗效的难度。希望「纯粹」双盲对照试验也有相当难度，最终是否止步于III期试验或「被流产」都是未知数。</p>","source":"lsy1584440308046","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“人民的希望”瑞德西韦让业界专家大失所望！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“人民的希望”瑞德西韦让业界专家大失所望！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-03-17 18:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg><strong>全球医生组织  </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir)，最新临床试验数据初步评估，让业界人士大失所望！\n这是最新传播方式认知：\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据，给出最乐观说法是「好坏参半或不及50%效果」。\n华尔街资深分析师表示在评估该项12名患者临床试验报告数据后，得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要！\n相关...</p>\n\n<a href=\"https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150330379","content_text":"被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir)，最新临床试验数据初步评估，让业界人士大失所望！\n这是最新传播方式认知：\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据，给出最乐观说法是「好坏参半或不及50%效果」。\n华尔街资深分析师表示在评估该项12名患者临床试验报告数据后，得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要！\n相关临床研究论文已发表在预印本服务器上。论文详述了12例新冠病毒患者的流行病学，临床病程和病毒学特征，包括3例接受瑞德西韦的治疗结果。该临床试验是由美国CDC应急小组人员开展的，确诊患者是从钻石公主号游轮接回来的患者。\n该报告称「对早期确诊的轻至中度新冠病毒感染患者进行了随机双盲对比治疗性试验，结果表明患者在疾病确诊后第二周出现恶化迹象。」\n具体讲，与未接受瑞德西韦治疗的患者相比，接受该药治疗患者的给氧需求，发烧和病毒感染症状改善之间没有「明显时间关联性」。\n该报告还陈述了服用瑞德西韦的患者出现恶心、呕吐、直肠出血和肝酶升高等不良反应(肝酶改变提示肝毒性潜在风险)，这表明该抗病毒治疗效果需要更长时间监测和观察。\n随着疫情全球大流行爆发，寻找药物治疗方法已经和疫苗研发同步进行了。今天由美国国立卫生研究院附属过敏与感染疾病研究所(NIH-NIAID) 主持的疫苗临床试验正式注射给第一位健康者，预期1-2月后才能初步评估安全性。\n吉利德研发的瑞德西韦是在去年埃博拉III期临床试验失败后被重新启用测试的。目前，在美国和中国还有其他4-5项临床试验同时进行中。吉利德也根据「同情法案」为数百名患者提供了该试验药品，本月底或下月初陆续还会有相关结果报道。\n业界专家认为新药临床试验，特别涉及目前重大疫情，所有试验药品和每项验证结果都会被反复仔细研究，寻找可能的有效迹象。因为无数患者期待着哪怕是微小希望(人民的希望)，包括最初个案例也会作为有价值线索分析。\n美国联邦政府的疫情特别行动小组专家指出，该论文尚未经过同行评审，试验结果还需要最终评估。FDA目前无法接受这样的数据审评。\n该论文作者指出「在美国确诊的患者总体疾病过程似乎比在中国观察到的患者要好些；大约42％的患者不需要住院治疗；但也提醒这一病情状况是否代表不同医疗水平或病毒谱系本身不断发演变展，仍有待研究」。\n还有业界人士提示该试验结果未经同行评审，在这种情况下各种已知药物引起的副作用可能会比通常情形下低很多。专家专家认为这是因为许多确诊患者已经服用了多种其他药，包括类固醇激素和抗生素等。\n此外，吉利德的「同情用药」通常针对病情恶化的患者。资深专家认为此药仍有可能缓减患者病情恶化。换句话说，该药应尽快给予患者以避免病情恶化，有可能产生一定效果。\n总之，鉴于目前临床试验小样本量和混合其他药品作用，凸显了评估该药临床疗效的难度。希望「纯粹」双盲对照试验也有相当难度，最终是否止步于III期试验或「被流产」都是未知数。","news_type":1},"isVote":1,"tweetType":1,"viewCount":2096,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":967154269,"gmtCreate":1584549731051,"gmtModify":1704354929725,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a><a href=\"https://laohu8.com/S/AYTU\">$Aytu BioScience, Inc.(AYTU)$</a><a href=\"https://laohu8.com/S/RHHBY\">$罗氏控股(RHHBY)$</a>这就是马爸爸今天运了50万套试剂盒去米国的后果吗？","listText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a><a href=\"https://laohu8.com/S/AYTU\">$Aytu BioScience, Inc.(AYTU)$</a><a href=\"https://laohu8.com/S/RHHBY\">$罗氏控股(RHHBY)$</a>这就是马爸爸今天运了50万套试剂盒去米国的后果吗？","text":"$Co-diagnostics Inc.(CODX)$$Aytu BioScience, Inc.(AYTU)$$罗氏控股(RHHBY)$这就是马爸爸今天运了50万套试剂盒去米国的后果吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/967154269","isVote":1,"tweetType":1,"viewCount":4197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":989239941,"gmtCreate":1582823562483,"gmtModify":1704347938970,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>&nbsp;多次喊停后，终于冷静下来了","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>&nbsp;多次喊停后，终于冷静下来了","text":"$Moderna, Inc.(MRNA)$ 多次喊停后，终于冷静下来了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/989239941","isVote":1,"tweetType":1,"viewCount":1928,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":953514935,"gmtCreate":1590484722327,"gmtModify":1704192614436,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LK\">$瑞幸咖啡(LK)$</a>回光返照吗？","listText":"<a href=\"https://laohu8.com/S/LK\">$瑞幸咖啡(LK)$</a>回光返照吗？","text":"$瑞幸咖啡(LK)$回光返照吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/953514935","isVote":1,"tweetType":1,"viewCount":16784,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":959456092,"gmtCreate":1589988177216,"gmtModify":1704191439128,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"自作孽，不可活","listText":"自作孽，不可活","text":"自作孽，不可活","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/959456092","repostId":"1127099160","repostType":4,"isVote":1,"tweetType":1,"viewCount":3090,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":965230655,"gmtCreate":1584014361677,"gmtModify":1704352447565,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a>财报又赶不出来了？","listText":"<a href=\"https://laohu8.com/S/CODX\">$Co-diagnostics Inc.(CODX)$</a>财报又赶不出来了？","text":"$Co-diagnostics Inc.(CODX)$财报又赶不出来了？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/965230655","isVote":1,"tweetType":1,"viewCount":2031,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":983314905,"gmtCreate":1583151900507,"gmtModify":1704348781072,"author":{"id":"3544167465922949","authorId":"3544167465922949","name":"淼淼小主","avatar":"https://static.tigerbbs.com/33649abbfb5accd98b132de52d3a8c14","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544167465922949","authorIdStr":"3544167465922949"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FTSV\">$Forty Seven Inc.(FTSV)$</a>吉利德以每股95.5美元收购47 65%的股份","listText":"<a href=\"https://laohu8.com/S/FTSV\">$Forty Seven Inc.(FTSV)$</a>吉利德以每股95.5美元收购47 65%的股份","text":"$Forty Seven Inc.(FTSV)$吉利德以每股95.5美元收购47 65%的股份","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/983314905","isVote":1,"tweetType":1,"viewCount":3237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}